$0.95
+0.02 (+2.33%)
Open$0.94
Previous Close$0.92
Day High$0.95
Day Low$0.88
52W High$1,030.00
52W Low—
Volume—
Avg Volume72.8K
Market Cap14.42M
P/E Ratio—
EPS$-136.77
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,083.5% upside
Current
$0.95
$0.95
Target
$11.19
$11.19
$8.32
$11.19 avg
$14.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.88M | 4.46M | 5.44M |
| Net Income | -169,945 | -168,167 | -171,039 |
| Profit Margin | -3.5% | -3.8% | -3.2% |
| EBITDA | -214,177 | -200,655 | -244,682 |
| Free Cash Flow | -155,731 | -123,018 | -136,236 |
| Rev Growth | -8.5% | +21.3% | +21.2% |
| Debt/Equity | 0.77 | 0.64 | 0.80 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |